Product Information
TREXALL 7.5 MG TABLET is a brand (anda) product labeled by Teva Women's Health, Inc., priced at $36.2091 per EA under NDC 51285036701. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on Mar 21, 2001.
The High Outlier badge above means this manufacturer's average price in the Methotrexate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
7.5 mg/1
Manufacturer
Teva Women's Health, Inc.NDC
51285036701
Classification
Brand (ANDA)
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
2/18/2026
Active Ingredients
METHOTREXATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA040385FDA Approved
3/21/2001
On Market Since
5/3/2001
Pharmacological Classes
Price Statistics
The NADAC for TREXALL 7.5 MG TABLET has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $36.2091 per EA |
|---|---|
| All-time high | $36.2091 (Sep 30, 2026) |
| All-time low | $36.2091 (Feb 18, 2026) |
| 52-week high | $36.2091 |
| 52-week low | $36.2091 |
| Median price | $36.2091 |
| Average price | $36.2091 |
| Largest weekly change | 0.0% (Feb 25, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methotrexate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Women's Health, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methotrexate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TREXALL 7.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TREXALL 7.5 MG TABLET, manufactured by Teva Women's Health, Inc., is $36.2091 per EA (NDC 51285036701), effective Sep 30, 2026.
How has the price of TREXALL 7.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for TREXALL 7.5 MG TABLET has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for TREXALL 7.5 MG TABLET?
Since Feb 18, 2026, the NADAC for TREXALL 7.5 MG TABLET has ranged from a low of $36.2091 (Feb 18, 2026) to a high of $36.2091 (Sep 30, 2026), with a median of $36.2091 per EA.
Are there cheaper alternatives to TREXALL 7.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of TREXALL 7.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TREXALL 7.5 MG TABLET?
TREXALL 7.5 MG TABLET (NDC 51285036701) is labeled by Teva Women's Health, Inc., and CMS classifies it as a brand (anda) product.